Research across Cancer
Related studies from across the Cancer family.
Kidney-directed SBRT shows modest renal function decline in inoperable patients
Small study shows kidney function drops after radiation for hard-to-treat tumors
This prospective phase 2 single-arm trial evaluated kidney-directed SBRT in 30 patients with primary or metastatic renal tumors who were med…
Radiation to treat kidney tumors may lower kidney function over two years, even when surgery is not an option.
Nephrometry Scores Show Limited Discrimination for Adverse Outcomes After RAPN in Larger Renal Tumors
Tumor complexity scores predict longer surgery time but not major complications in kidney cancer removal
This retrospective cohort study of 109 patients with pT1b–pT2a renal tumors found that PADUA and RENAL nephrometry scores had limited discri…
Scores measuring kidney tumor complexity predicted longer surgery time but failed to predict major complications in 109 patients.
Radical nephrectomy performed for renal inflammatory myofibroblastic tumor in an elderly female
Rare Kidney Tumor Treated Successfully With Surgery Alone
This is a case report of an elderly female patient who underwent radical right nephrectomy for a renal inflammatory myofibroblastic tumor.
A rare kidney tumor was removed with surgery, and no recurrence was seen at 6 months. But this is just one case.
Hong Kong consensus statement updates management for locally advanced and metastatic renal cell carcinoma
New Kidney Cancer Rules Change How Doctors Treat Metastasis
This guideline presents a consensus statement developed by 6 urologists and 8 clinical oncologists in Hong Kong regarding locally advanced a…
New expert rules update kidney cancer care with more drug options and clearer surgery plans.
Savolitinib and durvalumab combination yields response rates of 34% to 53% in papillary renal cancer patients
New Hope for a Tough Kidney Cancer Type
This single-arm phase II study evaluated savolitinib and durvalumab in 41 treatment-naïve or pretreated patients with papillary renal cancer…
A new drug pair breaks the shield blocking treatment for a rare kidney cancer type, offering patients a chance at longer survival after stan…
Simlukafusp alfa plus atezolizumab with or without bevacizumab shows antitumor activity in metastatic renal cell carcinoma
Does adding bevacizumab nearly triple the time before kidney cancer grows back?
A phase Ib randomized open-label study in 66 patients with metastatic renal cell carcinoma found objective response rates of 25% with simluk…
Adding bevacizumab nearly tripled the time before kidney cancer grew back compared to a two-drug mix in this early study.